For anti-PLA2R/TSHD7A Indirect Immunofluorescent Antibody Assay (IFA) development and related research
Primary membranous nephropathy (PMN) is a kidney-specific, autoimmune glomerular disease that presents with increased protein in the urine associated with a pathognomonic pattern of injury in glomeruli. MN is a rare disease with significant HLA Class II genetic restriction and yet with two autoantigens described, it displays a remarkably consistent immunopathology based on deposition of autoantibodies in the subepithelial side of the glomerular basement membrane (GBM), a similar clinical presentation and response to therapy.
In 2009, PLA2R was defined as the predominant autoantigen in 72% of primary membranous nephropathy (MN) cases by western blotting studies using patient serum autoantibodies .
THSD7A is defined as the second autoantigen in MN using a similar methodological approach but only accounts for a small amount (up to 2%) of MN cases.
Creative Diagnostics now can provide PLA2R and THSD7A high expressed stable cell lines, which can be used in PLA2R/TSHD7A autoantibody IFA development. Anti-PLA2R/THSD7A IFA Kit is also available for research use.
|Cat. No||Product Name||Price|
|CSC-PL01||PLA2R Stable Cell Line|
|CSC-TH01||THSD7A Stable Cell Line|
|DIFA-01||Anti-PLA2R IFA Kit (RUO)|
|DIFA-02||Anti-PLA2R/THSD7A IFA Kit (RUO)|
Figure 1 | Indirect immunofluorescence using anti-PLA2R positive serum in PLA2R stable cell line (a) and control cell line (b)
Figure 2 | Slides in CD Cat# DIFA-02
PLA2R-Test: PLA2R-transfected cells
PLA2R-Blank: Control transfected cells
TSHD7A-Test: TSHD7A-transfected cells
TSHD7A-Blank: Control transfected cells
PC & NC: PLA2R-transfected cells